Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses whether the treatment emergent adverse events (AEs) were consistent with the known safety profiles for belantamab mafodotin and pomalidomide.
Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses common adverse events (AEs) observed in patients with relapsed/refractory multiple myeloma following treatment with belantamab mafodotin in combination with pomalidomide and dexamethasone.
Hagop Kantarjian, MD, of the University of Texas MD Anderson Cancer Center, discusses what the interim analysis of the OPTIC trial demonstrated in terms of the safety and arterial occlusive events profiles with response-based ponatinib dosing regimens.
Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses the common prior therapies for patients with relapsed/refractory multiple myeloma who were enrolled in the ALGONQUIN trial.
Hagop Kantarjian, MD, of the University of Texas MD Anderson Cancer Center, discusses what the PACE trial was able to demonstrate in regard to patient response to ponatinib for patients with resistant and intolerant chronic-phase CML with substantial prior second-generation treatment.
Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses the dose limiting toxicities observed among patients with relapsed/refractory multiple myeloma following treatment with belantamab mafodotin in combination with pomalidomide and dexamethasone.
Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses what belantamab mafodotin and pomalidomide are, and how they work together to treat relapsed/refractory multiple myeloma.
Hagop Kantarjian, MD, of the University of Texas MD Anderson Cancer Center, discusses the reasons that the use of second-generation tyrosine kinase inhibitors in patients with chronic-phase CML who have failed one or more second-generation tyrosine kinase inhibitors needed further investigation.
Helen Thackray, MD, dives deeper into how the researchers tested rivipansel on the study participants and the implications compared to previous trials.
Helen Thackray, MD, provides a brief overview and highlights of the RESET clinical trial.
In an interview with Pharmacy Times, Stefan Behrens, PhD, CEO and co-founder of GYANT, and Justin Graham, MD, MS, chief medical officer, said preparing patients for the process of receiving a coronavirus disease 2019 (COVID-19) vaccine is essential.
Pharmacy Times® interviewed Christopher Moxham of Fulcrum Therapeutics, on his closing thoughts on the research he conducted into the induction of fetal hemoglobin by FTX6058.
Pharmacy Times® interviewed Charles Nakar, MD and Amy Shapiro, MD, of the Indiana Hemophilia & Thrombosis Center, on 3 new patient cases from their presentation and the significance of these cases to their research.
Pharmacy Times® interviewed Christopher Moxham of Fulcrum Therapeutics, on the results observed in his research when treating donors who were healthy or had sickle cell disease with FTX-6058.
Pharmacy Times® interviewed Charles Nakar, MD and Amy Shapiro, MD, of the Indiana Hemophilia & Thrombosis Center, on the process for the diagnosis of patients with congenital plasminogen deficiency.
Pharmacy Times® interviewed Christopher Moxham of Fulcrum Therapeutics, on what their parallel target identification efforts were able to identify, and how this identification was important in his research.
Hagop Kantarjian, MD, of the University of Texas MD Anderson Cancer Center, discusses what the response rates and survival outcomes were for ponatinib among patients who failed second-generation tyrosine kinase inhibitors in the OPTIC trial.
Pharmacy Times® interviewed Brady Stein, MD, MHSc, of the Feinberg School of Medicine at Northwestern University, on the implications of the results of his research on further investigation and treatment opportunities for patients with polycythemia vera.
Pharmacy Times® interviewed Brady Stein, MD, MHSc, of the Feinberg School of Medicine at Northwestern University, on the noteworthy results observed in the study in relation to cause of death among patients with polycythemia vera.
Pharmacy Times® interviewed Brady Stein, MD, MHSc, of the Feinberg School of Medicine at Northwestern University, on the issues existing around prior data on the causes of death for patients with polycythemia vera (PV) and why it was important to have greater clarity in this area.
Pharmacy Times® interviewed Charles Nakar, MD and Amy Shapiro, MD, of the Indiana Hemophilia & Thrombosis Center, on how airway obstruction and respiratory distress can impact pediatric patients versus adult patients.
Pharmacy Times® interviewed Charles Nakar, MD and Amy Shapiro, MD, of the Indiana Hemophilia & Thrombosis Center, on what the treatment options are for patients with congenital plasminogen deficiency with airway obstruction and respiratory distress.
Pharmacy Times® interviewed Christopher Moxham of Fulcrum Therapeutics, on what FTX-6058 is, how it was developed, and what it is able to treat.
Pharmacy Times® interviewed Christopher Moxham of Fulcrum Therapeutics, on how maintaining expression of the anti-sickling gamma ortholog could be beneficial for children and adults with sickle cell disease, and why this is important to investigate.
Pharmacy Times® interviewed Charles Nakar, MD and Amy Shapiro, MD, of the Indiana Hemophilia & Thrombosis Center, on the common manifestations of congenital plasminogen deficiency, and whether it is life threatening for patients.
Pharmacy Times® interviewed Brady Stein, MD, MHSc, of the Feinberg School of Medicine at Northwestern University, on the common treatments for patients with polycythemia vera.
Pharmacy Times® interviewed Brady Stein, MD, MHSc, of the Feinberg School of Medicine at Northwestern University, on the survival estimates for patients with polycythemia vera in the past and the mortality rates among these patients.
Pharmacy Times® interviewed Brady Stein, MD, MHSc, of the Feinberg School of Medicine at Northwestern University, on what polycythemia vera (PV) is and why it was important to understand mortality and causes of death among patients with PV.
Pharmacy Times® interviewed Christopher Moxham of Fulcrum Therapeutics, on what sickle cell disease and beta-thalassemias are caused by, and how hemoglobin gamma can prevent or reduce disease-related pathophysiology in these disorders.
Pharmacy Times spoke with Angela Kashuba, Dean of UNC Eshelman School of Pharmacy and Patrick Brown, UNC Eshelman School of Pharmacy Alumni, about the importance of preparing pharmacists and students to vaccinate the general public with the COVID-19 vaccine.
